8 results
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... hypoglycaemic agents #Diabetes ... #Diabetic #Medications ... #Pharmacology # ... Impairment #CKD #Table
Antiplatelet Medications - Summary Table

Aspirin - Inhibits cyclooxygenase, preventing formation of thromboxane A2
 • Acute coronary
Antiplatelet Medications ... - Summary Table ... of stroke • As ... #Summary #Table ... #Pharmacology
PDE5 inhibitors are usually the drugs of first choice for erectile dysfunction.

PDE5 inhibitors enhance an erection that is
partially developing as ... #pharmacology #comparison ... #treatment #medications ... #dosing #drugs ... #table #pharmacotherapy
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
Normal and Renal Dosing ... different than other medications ... #Renal #Dosing ... #Pharmacology #Management ... #Diabetes #DM2
The 8 A’s — drugs that interact with warfarin
Antibiotics 
 - Most agents, but especially co-trimoxazole,
cyclooxygenase-2 inhibitors ... Gingko biloba, dong ... #Interactions #Table ... #Mnemonic #8As ... #Pharmacology #Medications
Daliresp (Roflumilast) 
Indication: Reduce risk of COPD exacerbations 
Drug Class: Selective Phosphodiesterase-4 (PDE4) Inhibitor 
GOLD 2019
Roflumilast) Indication ... Phosphodiesterase-4 (PDE4) Inhibitor ... Eosinophils < 100 Dosing ... : 250 mcg tablet ... #Pharmacology #
Veltassa (Patiromer) 
MECHANISM: Potassium Binder 
INDICATION: Treatment of Hyperkalemia 
FORMULATION: Powder for oral suspension 
DOSING: 8.4
Potassium Binder INDICATION ... oral suspension DOSING ... with CKD, HF, or diabetes ... ACE inhibitors, ... #Hyperkalemia #Pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... drug to remain stable ... take any other medications ... #semaglutide #Diabetes ... #Pharmacology #